Indivior reported 122M in Selling and Administration Expenses for its fiscal semester ending in March of 2026.





Selling And Administration Expenses Change Date
AstraZeneca USD 5.8B 735M Jun/2026
Cassava Sciences USD 3.89M 2.77M Mar/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Glaxosmithkline GBP 2.12B 1.44B Mar/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Roche Holding CHF 6.37B 908M Jun/2026
West Pharmaceutical Services USD 117.6M 18.1M Jun/2026